Company Description
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions.
The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy.
Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum.
Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis.
The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology.
Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 4, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Reid Waldman |
Contact Details
Address: 470 James Street, Suite 14 New Haven, Connecticut 06513 United States | |
| Phone | (228) 372-3376 |
| Website | veradermics.com |
Stock Details
| Ticker Symbol | MANE |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001827635 |
| CUSIP Number | 922967104 |
| ISIN Number | US9229671048 |
| Employer ID | 84-3304423 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Reid Waldman M.D. | Chief Executive Officer and Director |
| Dominic Carrano CPA | Chief Financial Officer and Treasurer |
| Dr. Timothy Durso M.D. | Chief Technical Officer |
| Michael V. Greco J.D. | General Counsel and Secretary |
| Karl Pruss | Senior Director of Manufacturing Sciences and Technology |
| Michael Murphy R.Ph. | Vice President of Project and Program Management of Business Technology and Chief of Staff |
| Mark Neumann | Chief Commercial and Strategy Officer |
| Erika Sipperly CPA | Controller |
| Dr. Michael Smolinski Ph.D. | Vice President of Development and Scientific Operations |
| Aron Shapiro | Vice President of Clinical Development and Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | FWP | Free Writing Prospectus |
| Apr 27, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 27, 2026 | 8-K | Current Report |
| Apr 27, 2026 | 8-K | Current Report |
| Apr 6, 2026 | DRS | [Cover] Draft Registration Statement |
| Mar 30, 2026 | 10-K | Annual Report |
| Mar 30, 2026 | 8-K | Current Report |
| Feb 12, 2026 | SCHEDULE 13D | Filing |
| Feb 12, 2026 | SCHEDULE 13G | Filing |
| Feb 11, 2026 | SCHEDULE 13D | Filing |